

Publikationen - Zeitschriften

2019

1. Goldman HB, Oelke M, Kaplan SA, Kitta T, Russell D, Carlsson M, Arumi D, Mangan E, Ntanios F (2019) Do patient characteristics predict which patients with overactive bladder will achieve better outcomes with a higher dose of fesoterodine? *Int Urogynecol J.* 30: 239 – 244.
2. D'Ancona C, Haylen BT, Oelke M, Abranches-Monteiro L, Arnold E, Goldman H, Hamid R, Homma Y, Marcelissen T, Rademakers K, Schizas A, Singla A, Soto I, Tse V, de Wachter S, Herschorn S (2019) The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. *Neurourol Urodyn.* 38: 433 – 477.
3. Uren A, Cotterill N, Harding C, Hillary C, Chapple C, Lasch K, Stroupe A, Deshpande C, Delbecque L, van Koevinge G, Oelke M, Belal M, Bosch R, Blok B, Nitti V, Gotoh M, Takei M, Crawford B, Klaver M, Bongaerts D, Hakimi Z, Kos T, Abrams P (2019) The development of the ICIQ-UAB: a patient reported outcome measure for underactive bladder. *Neurourol Urodyn.* 38: 996 – 1004.
4. Bschiepfer T, Oelke M, Rieken M (2019) Diagnostik und diagnostische Strategie beim benignen Prostatasyndrom (BPS) – ein Überblick [Diagnostic procedures and diagnostic strategy for lower urinary tract symptoms/benign prostatic hyperplasia : An overview]. *Urologe A.* 58: 238 – 247.
5. Oelke M, Bschiepfer T, Höfner K (2019) Hartnäckige Mythen zum Thema BPS – und was davon wirklich stimmt! [Fake News BPH - what is really true!] *Urologe A.* 58: 271 – 283.
6. Oelke M, Addali M, Reisenauer C (2019) What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder. *Arch Gynecol Obstet.* 299: 1243 – 1252.
7. Mühlstädt S, Oelke M (2019) Akuter Harnverhalt bei Männern: Die Wirksamkeit bei Alpha-Blockern beim Katheterauslassversuch nach Harnverhalt [Acute urinary retention in men: efficacy of alpha-blockers in catheter removal after urinary retention]. *Urologe A.* 58: 680 – 685.
8. Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, Amarenco G, Gamé X, Kirby R, van der AA, Cornu JN (2019) A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. *Eur Urol.* 75: 988 – 1000.
9. Ankolekar A, Vanneste BG, Bloemen-van Gorp E, van Roermund JG, van Limbergen EJ, van de Beek K, Zambon V, Oelke M, Dekker A, Roumen C, Lambin P, Berlanga A, Fijten R (2019) Development and validation of a patient decision aid for prostate cancer therapy: towards more participative shared decision making. *BMC Med Inform and Decis Mak.* 19: 130.
10. Somani BK, Van Cleynenbreugel B, Gözen A, Palou J, Barmoshe S, Biyani S, Gaya JM, Hellawell G, Pini G, Oscar FR, Sanchez Salas R, Macek P, Skolarikos A, Wagner C, Eret V, Haensel S, Siena G, Schmidt M, Klitsch M, Vesely S, Ploumidis A, Proietti S, Kamphuis G, Tokas T, Geraghty R, Veneziano (2019) The European urology residents education programme hands-on training format: 4 years of hands-on training improvements from the European School of Urology. *Eur Urol Focus.* 5: 1152 – 1156.

11. Oelke M, Burkart M (2019) Benignes Prostatasyndrom – Strategien für eine langfristig erfolgreiche medikamentöse Therapie: Sprechen, Individualisieren, Nachverfolgen (SINN). *urologen.info*. 17: 94 – 96.
12. Oelke M (2019) Bänder und Netze zur Behandlung der weiblichen Harninkontinenz oder des urogenitalen Deszensus bald auch in Deutschland verboten? Ein Update zu den internationalen Verboten von alloplastischem Material aus deutscher Sicht. *urologen.info*. 17: 212 – 213.

2020

1. Höfner K, Hampel C, Kirschner-Hermanns R, Alloussi SH, Bauer RM, Bross S, Bschleipfer T, Goepel M, Haferkamp A, Hüscher T, Kaufmann A, Kiss G, Kranz J, Oelke M, Pannek J, Reitz A, Rutkowski M, Schäfer W, Schulte-Baukloh H, Schumacher S, Schulte-Baukloh H, Seif C, Schultze-Lampel D (2020) Stellungnahme des Arbeitskreises Urologische Funktionsdiagnostik und Urologie der Frau der Akademie der Deutschen Gesellschaft für Urologie zum Einsatz von synthetischen Band- und Netzimplantaten in der Behandlung von Belastungsinkontinenz und Deszensus genitalis der Frau. [Use of synthetic slings and mesh implants in the treatment of female stress urinary incontinence and prolapse: Statement of the Working Group on Urological Functional Diagnostics and Female Urology of the Academy of the German Society of Urology] *Urologe A*. 59: 65 – 71.
2. D'Agate S, Wilson T, Adalig B, Manyak M, Palacios-Moreno JM, Chavan C, Oelke M, Roehrborn C, Della Pasqua O (2020) Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH. *World J Urol*. 38: 463 – 472.
3. Mostafaei H, Sadeghi-Bazargani H, Hajebrahimi S, Salehi-Pourmehr H, Gojazadeh M, Onur R, Al Mousa RT, Oelke M (2020) Prevalence and associated risk factors of female urinary incontinence in the developing world: a systematic review and meta-analysis. A report from the developing world committee of the International Continence Society. *Neurourol Urodyn*. 39: 1063 – 1086.
4. Somani BK, Van Cleynenbreugel B, Gözen A, Skolarikos A, Wagner C, Beatty J, Barmoshe S, Gaya Sopena JM, Kalogeropoulos T, Rodriguez Faba O, Sanchez Salas R, Schmidt M, Siena G, Pini G, Palou J, Geraghty R, Veneziano D (2020) Outcomes of European basic laparoscopic skills (EBLUTS) examinations: results from European School of Urology (ESU) and EAU Section of Uro-Technology (ESUT) over 6 years (2013 – 2018). *Eur Urol Focus*. 6: 1190 – 1194.
5. Saar M, Linxweiler J, Borkowetz A, Fussek S, Urbanova K, Bellut L, Kristiansen G, Wullich B; German Prostate Cancer Consortium (DPKK) (2020) Current role of multiparametric MRI and MRI targeted biopsies for prostate cancer diagnosis in Germany: a nationwide survey. *Urol Int*. 104: 731 – 740.
6. Harke NN, Radtke JP, Bach C, Berger FP, Blana A, Borgmann H, Distler FA, Edeling S, Egner T, Farzat M, Haese A, Hein R, Kuczyk MA, Moritz R, Musch M, Peters I, Pokupic S, Schneider A, Schumann A, Schwentner C, Sighinolfi CHM, Buse S, Stolzenburg JU, Truß MC, Waldner M, Wülfing C, Witt JH, Wagner C (2020). To defer or not to defer? A German longitudinal multicentric assessment of clinical practice in urology during the COVID-19 pandemic. *Plos One* 15: e0239027.
7. Wagner C, Addali M, Witt JH (2020) Roboterassistierte radikale Prostatektomie. *Aktuelle Urol*. 51: 483 – 499.

8. Madersbacher S, Roehrborn CG, Oelke M (2020) The role of novel minimally invasive treatments for lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). *BJU Int.* 126: 317 – 326.
9. Madersbacher S, Oelke M, Häcker A, Bschiepfer T (2020) Differenziertes operatives Management unterschiedlicher Patienten mit benignem Prostatasyndrom (BPS) [Sophisticated surgical management of distinctive patients with benign prostatic hyperplasia]. *Urologe A.* 59: 1168 – 1176.
10. Moll FH, Oelke M (2020) Die Stadieneinteilung nach Alken – Eine deutsch-französische Affäre [The Alken stages – a German-French affair]. *Urologe A.* 59: 1208 – 1216.
11. Abranches-Monteiro L, Hamid R, D’Ancona D, AlHasso A, Dmochowski R, Ecclestone H, Al Mousa R, Onur R, Shah S, Vasudeva P, Vilas V, Oelke M (2020) The International Continence Society (ICS) report on the terminology for male lower urinary tract surgery. *Neurourol Urodyn.* 39: 2072 – 2088.
12. Liakos N, Mendrek MA, Witt JH, Wagner C (2020) Robot-Assisted Nerve-Sparing Excision of a Symptomatic Obturator Nerve Schwannoma: A Case Report. *Cureus.* 12(11): e11468.
13. Hamann C, Naumann M, Addali M, Witt JH, Kollitsch J, Wagner C, M. Hamann M, Jünemann KP, Osmonov D (2020) Multizentrischer Vergleich von Komplikationen nach roboter-assistierter und offen chirurgischer Prostataadenomenektomie. *Urologe A.* 59: 565 – 572.
14. Oelke M (2020) Benignes Prostatasyndrom – Basiswissen und Epidemiologie. *Med Monatsschr Pharm.* 43: 293 – 295.
15. Oelke M (2020) Benignes Prostatasyndrom – Diagnostik. *Med Monatsschr Pharm.* 43: 296 – 299.
16. Oelke M (2020) Benignes Prostatasyndrom – Konservative und medikamentöse Therapie. *Med Monatsschr Pharm.* 43: 300 – 305.
17. Oelke M (2020) Benignes Prostatasyndrom – Chirurgische Therapie. *Med Monatsschr Pharm.* 43: 306 – 310.
18. Oelke M (2020) Benignes Prostatasyndrom – Patientenfall. *Med Monatsschr Pharm.* 43: 311 – 312.

2021

1. Leyh-Bannurah SR, Kachanov M, Karakiewicz PI, Beyersdorff D, Pompe RS, Oh-Hohenhorst SJ, Fisch M, Maurer T, Graefen M, Budäus L. (2021) Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer. *World J Urol.* 39: 81 – 88.
2. Amiri M, Schneider T, Oelke M, Murgas S, Michel MC (2021) Factors associated with decisions for initial dosing, up-titration of propiverine and treatment outcomes in overactive bladder syndrome patients in a non-interventional setting. *J Clin Med.* 10: 311.
3. De Nuncio C, Brucker B, Bschiepfer T, Cornu JN, Drake MJ, Fusco F, Gravas S, Oelke M, Peyronnet B, Tutolo M, van Koeveeringe G, Madersbacher S (2021) Beyond antimuscarins: a review of pharmacological and interventional alternatives for OAB management. *Eur Urol.* 79: 492 – 504.

4. Oderda M, Diamond R, Ablisinni S, Callaris G, Carbone A, Falcone M, Fiard G, Gandaglia G, Marquis A, Marra G, Parola C, Pastore A, Peltier A, Ploussard G, Roumeguere T, Sanchez-Salas R, Simone G, Smelzo S, Witt JH, Gontero P (2021) Indications for and complications of pelvic lymph node dissection in prostate cancer: accuracy of available nomograms for the prediction of lymph node invasion. *BJU Int.* 127: 318 – 325.
5. John H, Wagner C, Padevit C, Witt JH (2021) From open simple to robotic-assisted simple prostatectomy (RASP) for large benign prostate hyperplasia: the time has come *World J Urol.* 39: 2329 – 2336.
6. Harke NN, Wagner C, Liakos N, Urbanova K, Addali M, Hadaschik B, Witt JH (2021) Superior early and long-term continence following early micturition on day 2 after robot-assisted radical prostatectomy: a randomized prospective trial. *World J Urol.* 35: 771 – 777.
7. Milsom I, Wagg A, Oelke M, Chapple C (2021) Which drugs are best for overactive bladder? From patients' expectations to physicians' decisions. *Int J Clin Pract.* 75: e13870.
8. D'Agate S, Chavan C, Manyak M, Palacios-Moreno JM, Oelke M, Michel MC, Roehrborn CG, Della Pasqua O. (2021) Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms. *Br J Clin Pharmacol.* 87: 2777 – 2789.
9. D'Agate S, Chavan C, Manyak M, Palacios-Moreno JM, Oelke M, Michel MC, Roehrborn CG, Della Pasqua O. (2021) Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression. *World J Urol.* 39: 2635 – 2643.
10. D'Agate S, Chavan C, Manyak M, Palacios-Moreno JM, Oelke M, Michel MC, Roehrborn CG, Della Pasqua O (2021) Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms. *Br J Clin Pharmacol.* 87: 2777 – 2789.
11. Leyh-Bannurah SR, Liakos N, Oelke M, Wagner C, Schuette A, Fangmeyer B, Zinke J, Wasiri D, Mendrek M, Witt JH (2021) Perioperative and postoperative outcomes of robot-assisted radical prostatectomy in prostate cancer patients with prior transurethral subvesical deobstruction: results of a high-volume center. *J Urol.* 206: 308 – 318.
12. Leyh-Bannurah SR, Wagner C, Schuette A, Liakos N, Karagirotis T, Mendrek M, Rachubinski P, Urbanova K, Oelke M, Witt JH (2021) Improvement of quality of life and symptom burden after robot-assisted radical prostatectomy in patients with moderate to severe LUTS. *Sci Rep.* 11: 16757.
13. Wagg AS, Herschorn S, Carlsson M, Fernet M, Oelke M (2021) What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine. *Neurourol Urodyn.* 40: 1559 - 1568.
14. von Hardenberg J, Cash H, Koch D, Borkowetz A, Bruendl J, Leyh-Bannurah SR, Kuru TH, Kowalewski KF, Schindele D, Mala KS, Westhoff N, Blana A, Schostak M; Working Group of Focal and Microtherapy of the German Society of Urology (DGU)(2021) Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer. *World J Urol.* 39: 3747 – 3754.
15. Vanneste BG, van Limbergen EJ, Marcelissen TA, van Roermund JG, Lutgens LC, Arnoldussen CW, Lambin P, Oelke M (2021) Evidence-based management algorithm for acute and chronic radiation cystitis and urethritis. *Urologia Int.* 106: 63 – 74.

1. Karagiotis T, Witt JH, Jankowski T, Mendrek M, Wagner C, Schuette A, Liakos N, Rachubinski P, Urbanova K, Oelke M, Kachanov M, Leyh-Bannurah SR (2022). Two-year quality of life after robot-assisted radical prostatectomy according to pentafecta criteria and cancer of the prostate risk assessment (CAPRA-S) *Sci Rep.* 12: 244.
2. Haylen B, Oelke M. (2022) Clinical definition of pelvic organ prolapse - if it ain't broke.... *Neurourol Urodyn.* 41: 506 – 507.
3. Liakos N, Witt JH, Rachubinski P, Leyh-Bannurah SR (2022) The dilemma of misclassification rates in senior patients with prostate cancer, who were treated with robot-assisted radical prostatectomy: implications for patient counseling and diagnostics. *Front Surg.* 9: 838477.
4. Kachanov M, Leyh-Bannurah SR, Roberts MJ, Sauer M, Beyersdorff D, Boiko S, Maurer T, Steuber T, Graefen M, Budäus L (2022) Optimizing combined magnetic resonance imaging (MRI)-targeted and systematic biopsy strategies: sparing the multiparametric MRI-negative transitional zone in presence of exclusively peripheral multiparametric MRI-suspect lesions. *J Urol.* 207: 333 – 340.
5. Harke NN, Wagner C, Hermann RM, Hadaschik BA, Radtke JP, Altay-Langguth A, Aufderklamm S, Bach C, Becker-Schiebe M, Blana A, Bruns F, Buse S, Combs SE, Engels CL, Ezzibdeh E, Fiedler M, Fischer LA, Farzat M, Frismann A, Heck MM, Henkenberens C, Roesch MC, Käding C, Klautke G, Krausewitz P, Kuczyk MA, Leitsmann C, Lettmaier S, Mahjoub S, Manseck A, Medenwald D, Meyer A, Micke O, Moritz R, Ott M, Peters I, Pokupic S, Porres D, Preisser F, Reichel K, Schneider A, Schwentner C, Scobioala S, Truss M, Wegener D, Wezel F, Willborn K, Witt JH, Wittig A, Wittlinger M, Wolff HA, Zimmermanns V, Christiansen H (2022) Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment. *PLoS One.* 17: e0269827.
6. Müderrisoglu AE, Oelke M, Schneider T, Murgas S, de la Rosette JJMCH, Michel MC (2022) What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine. *Adv Ther.* 39: 2489 – 2501.
7. Sarychev S, Witt JH, Wagner C, Oelke C, Schuette A, Liakos A, Karagiotis K, Mendrek M, Kachanov M, Graefen M, Vetterlein MW, Meyer CP, Tian Z, Leyh-Bannura SR (2022) Impact of obesity on perioperative, functional and oncological outcomes after robotic-assisted radical prostatectomy in a high-volume center. *World J Urol.* 40: 1419 – 1425.
8. van Till JWO, Arita E, Kuroishi K, Croy R, Oelke M, van Koevinge GA, Chapple CR, Yamaguchi O, Abrams P (2022) Muscarinic-3-receptor positive allosteric modulator ASP8302 in patients with underactive bladder. A randomized controlled trial. *Neurourol Urodyn.* 41: 1139 – 1148.
9. Mendrek M, Witt JH, Sarychev S, Liakos N, Addali M, Wagner C, Karagiotis T, Schuette A, Soave A, Fisch M, Reinisch J, Herrmann T, Vetterlein MW, Leyh-Bannurah SR (2022) Reporting and grading of complications for intracorporeal robot-assisted radical cystectomy: an in-depth short-term morbidity assessment using the novel Comprehensive Complication Index® *World J Urol.* 40: 1679 – 1688.
10. Leyh-Bannurah SR, Boiko S, Beyersdorff D, Falkenbach F, Ekrutt J, Maurer T, Graefen M, Kachanov M, Budäus L (2022) Pan-segmental intraprostatic lesions involving mid-gland and apex of prostate (mid-apical lesions): assessing the true value of extreme apical biopsy cores. *World J Urol.* 40: 1653 – 1659.

11. Leyh-Bannurah SR, Wagner C, Schuette A, Addali M, Liakos N, Urbanova K, Mendrek M, Oelke M, Witt JH (2022) The impact of age on pathological insignificant prostate cancer rates in contemporary robot-assisted prostatectomy patients despite active surveillance eligibility. *Minerva Urol Nephrol.* 74: 437 – 444.
12. Kachanov M, Budäus L, Beyersdorff D, Karakiewicz PI, Tian Z, Falkenbach F, Tilki D, Maurer T, Sauter G, Graefen M, Leyh-Bannurah SR Targeted (2022) Multiparametric magnetic resonance imaging/ultrasound fusion biopsy for quantitative Gleason 4 grading prediction in radical prostatectomy specimens: implications for active surveillance candidate selection. *Eur Urol Focus.* 29: S2405 – 4569.
13. Wagg AS, Herschorn S, Carlsson M, Fernet M, Oelke M (2022) A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder. *J Comp Eff Res.* 11: 919 – 925.
14. Gravas S, Palacios-Moreno JM, Thompson D, Concas F, Kamola PJ, Roehrborn CG, Oelke M, Kattan MW, Averbeck MA, Manyak M, Cortés V, Lulic Z (2022) Understanding treatment response in individual profiles of men with prostatic enlargement at risk of progression. *Eur Urol Focus.* 16: S2405 – 4569.
15. Witt JH, Friedrich M, Jandrig B, Porsch M, Baumunk D, Liehr UB, Wendler JJ, Schostak M (2022) Molecular margin status after radical prostatectomy using glutathione S-transferase P1 (GSTP1) promoter hypermethylation *BJU Int.* 130: 454 – 462.
16. Leyh-Bannurah SR, Wagner C, Schuette A, Liakos N, Karagiannis T, Mendrek M, Rachubinski P, Oelke M, Tian Z, Witt JH (2022) Feasibility of robot-assisted radical prostatectomy in men at senior age 75 years: perioperative, functional and oncological outcome. *Aging Male.* 25: 8 – 16.
17. Kachanov M, Vetterlein MW, Soave A, Karakiewicz PI, Liakos N, Jankowski T, Pose RM, Mandrek M, Fisch M, Witt JH, Graefen M, Leyh-Bannurah SR (2022) Oncological impact of concomitant prostate cancer characteristics at the time of radical cystoprostatectomy for bladder cancer: a population-based analysis. *Aging Male.* 25: 54 – 61.
18. Ekrutt J, Leyh-Bannurah SR, Knipper S, Schramm F, Beyer B, Maurer T, Graefen M, Budäus L (2022) Increasing the attractiveness of surgical disciplines for students: Implications of a robot-assisted hands-on training course for medical education. *Front Surg.* 21: 953565.
19. Gloger S, Ubrig B, Boy A, Leyh-Bannurah SR, Siemer S, Arndt M, Stolzenburg JU, Franz T, Oelke M, Witt JH (2022) Bilateral peritoneal flaps reduce incidence and complications of lymphoceles after robotic radical prostatectomy with pelvic lymph node dissection - Results of the prospective randomized multicenter trial ProLy. *J Urol.* 208: 333 – 340.
20. Gravas S, Palacios-Moreno JM, Thompson D, Concas F, Kamola PJ, Roehrborn CG, Oelke M, Kattan MW, Averbeck MA, Manyak M, Cortes V, Lulic Z (2022) Understanding treatment response in individual profiles of men with prostatic enlargement at risk of progression. *Eur Urol Focus.* 16: S2405-4569(22)00165-1.
21. Martinelli E, Cindolo L, Grossi FS, Kuczyk MA, Siena S, Oelke M (2022) Transurethral water vapor ablation of the prostate with the Rezum system: urodynamic findings. *Neurourol. Urodyn.:* in press.
22. Rieken M, de Nunzio C, Cornu JN, Ramasamy R, Misrai V, Malde S, Oelke M, Gacci M, Madersbacher S (2022) Medical treatment incidence and persistence after surgical relief of lower urinary tract symptoms suggestive of benign prostatic obstruction: a critical analysis of the literature. *Eur Urol.* in press.

23. Naumann G, Aigmüller T, Bader W, Bauer R, Beilecke K, Betschart Meier C, Bruer G, Bschleipfer T, Deniz M, Fink T, Gabriel B, Gräble R, Grothoff M, Haverkamp A, Hampel C, Henscher U, Hübner M, Huemer H, Kociszewski J, Kölbl H, Kölle D, Kropshofer S, Kuhn A, Nothacker M, Oelke M, Peschers U, Preyer O, Schultz-Lampel D, Tamussino K, Tholen R, Tunn R, Viereck V, Reisenauer C (2022) Diagnostik und Therapie der Harinkontinenz der Frau. Leitlinie der DGGG, OEGGG und SGGG (S2k-Level, AWMF-Registernummer 015/091 (Januar 2022): Teil 1 mit Empfehlungen zur Diagnostik, konservativer und medikamentöser Therapie. *Geburtshilfe Frauenheilkd.*: in press.
24. Naumann G, Aigmüller T, Bader W, Bauer R, Beilecke K, Betschart Meier C, Bruer G, Bschleipfer T, Deniz M, Fink T, Gabriel B, Gräble R, Grothoff M, Haverkamp A, Hampel C, Henscher U, Hübner M, Huemer H, Kociszewski J, Kölbl H, Kölle D, Kropshofer S, Kuhn A, Nothacker M, Oelke M, Peschers U, Preyer O, Schultz-Lampel D, Tamussino K, Tholen R, Tunn R, Viereck V, Reisenauer C (2022) Diagnostik und Therapie der Harninkontinenz der Frau. Leitlinie der DGGG, OEGGG und SGGG (S2k-Level, AWMF-Registernummer 015/091 (Januar 2022): Teil 2 mit Empfehlungen zu interventioneller / operativer Therapie der überaktiven Harnblase, der operativen Therapie der Belastungsinkontinenz und Diagnostik und Therapie iatrogenen urogenitalen Fisteln. *Geburtshilfe Frauenheilkd.*: in press.
25. Vetterlein MW, Leyh-Bannurah SR (2022) Predefined and standardized complication catalogs: an essential tool to assess reproducible estimates of overall morbidity after urologic surgery. *J Endourol.*: in press.
26. Rachubinski P, Witt JH, Budäus L, Zinke J, Fangmeyer B, Spieker T, Vetterlein M, Rahbar K, Kachanov M, Leyh-Bannurah SR (2022) Precision-guidance vs systematic sampling: optimizing biopsy assessment of secondary prostate cancer suspicious multiparametric magnetic resonance imaging lesions. *J Urol.*: in press.